Men who were treated with vasoactive drugs capable of purifyingplasma – a plasma that contains both male and female hormone-producing cells – have a slightly lower risk of receiving a response to hormone-targeting drugs. These men may also have less difficulty eliminating tumor cells with skin cancer.

Surprisingly some prostate cancer patients whose tumors were treated with transrectal vasoactive drugs (TRAV) indicated the same as those receiving placebo vasoactive contraceptives found a significant reduction in their cancer growth rate (CGR) and a marked improvement of their clinical status. The results by the National Cancer Institute research team underline the importance of testing and validating the use of this investigational class of drugs for men with prostate cancer.

To conduct the study Puneet Chugh MD investigator and J. Keith Moley Chair for Morbidity and Morbidity Outcomes Research in the TRAV research program of the National Cancer Institute and his team imaged the outcomes of 43 patients 67 women who were treated with TRAV between January 2004 and January 2005 in a randomized double-blinded placebo-controlled trial. To perform this clinical trial HIV-infection and single-grip point tests were used to determine F2-isotope-label therapy (F2-HPT) response. F2-HPT is commonly prescribed for treatment of men with prostate and other benign tumors and is now approved by the U. S. Food and Drug Administration to treat patients with a variety of solid tumors.

Next study investigators performed the standard F2-HPT method by magnetic resonance analysis (MRA) with a cumulative effect of 89 sensitivity and 88 specificity. Results showed higher sensitivity and better specificity among TRAV-treated patients with CGR (median 9. 1 sensitivity 99. 7 specificity) than among control subjects (median 8. 8 sensitivity 91. 1 specificity). Bars represent mean SD of the correlation between MRA TRAV and CGR measures commonly used at UAB as a screening tool for prostate cancer.

Further by analyzing blood samples from the entire cohort investigators were able to achieve statistical significance in an analysis of blood samples from 21 men 9 women who were treated with TRAV in multiple procedures.

Further studies are needed to validate the findings and confirm the benefit of the use of F2-HPT as a screening tool for prostate cancer. The study was funded by the National Institutes of Health.

The senior author is Marcus Nelson PhD from UAB.